Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

fluorine F 18 fluoro-PEG6-IPQA

A radioconjugate containing the tracer PEG6-IPQA labeled with fluorine F 18 for potential tumor imaging using positron emission tomography (PET). Upon administration, the IPQA moiety of fluorine F 18 fluoro-PEG6-IPQA selectively targets and irreversibly binds to the constitutively active mutant L858R of epidermal growth factor receptor (EGFR) kinase, thereby allowing the visualization of tumor cells expressing the active mutant L858R EGFR using PET. This can be used to select EGFR kinase inhibitors that bind in a similar manner as this tracer and may allow individualized therapy for patients that respond well to these types of EGFR kinase inhibitors. The presence of the L858R EGFR mutation in non small cell lung cancer (NSCLC) cells is correlated with a better response to EGFR kinase inhibitors compared to wild-type (WT) or L858R/T790M EGFR dual-mutant.
Synonym:18F-fluoro-PEG6-IPQA
Abbreviation:[(18)F]F-PEG6-IPQA
Chemical structure:4-[(3-iodophenyl)amino]-7-(2-[2-{2-(2-[2-{2-(18F-fluoroethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}-ethoxy]-quinazoline-6-yl-acrylamide)
Search NCI's Drug Dictionary